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A complex inflammatory process mediated by proinflammatory cytokines and prostaglandins commonly occurs in the synovial tissue
of patients with joint trauma (JT), osteoarthritis (OA), and rheumatoid arthritis (RA). This study systematically investigated the
distinct expression profile of prostaglandin E2 (PGE2), its processing enzymes (COX-2), and microsomal PGES-1 (mPGES-1) as
well as the corresponding prostanoid receptor subtypes (EP1-4) in representative samples of synovial tissue from these patients (JT,
OA, and RA). Quantitative TaqMan®-PCR and double immunofluorescence confocal microscopy of synovial tissue determined the
abundance and exact immune cell types expressing these target molecules. Our results demonstrated that PGE2 and its processing
enzymes COX-2 and mPGES-1 were highest in the synovial tissue of RA, followed by the synovial tissue of OA and JT patients.
Corresponding prostanoid receptor, subtypes EP3 were highly expressed in the synovium of RA, followed by the synovial tissue of
OA and JT patients. These proinflammatory target molecules were distinctly identified in JT patients mostly in synovial
granulocytes, in OA patients predominantly in synovial macrophages and fibroblasts, whereas in RA patients mainly in synovial
fibroblasts and plasma cells. Our findings show a distinct expression profile of EP receptor subtypes and PGE2 as well as the
corresponding processing enzymes in human synovium that modulate the inflammatory process in JT, OA, and RA patients.
1. Introduction
Arthritis describes an inflammatory process of a joint which
mainly affects the synovial tissue leading to tissue damage
and fibrosis [1, 2]. It is very complex and can occur in multi-
ple different ways, e.g., as a consequence of joint trauma (JT),
as a leading cause of osteoarthritis (OA), or as a trigger for
the autoimmune disease rheumatoid arthritis (RA) [1]. This
process is driven by various inflammatory mediators such
as tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β),
and macrophage-colony stimulating factor, as well as
prostaglandin E2 (PGE2) and its processing enzyme cycloox-
ygenase 2 (COX2) [3]. Recently, we demonstrated an overex-
pression of the synovial proinflammatory mediators such as
IL-1β, TNF-α, and 5-LOX concomitant with the progress of
synovial inflammation in JT, OA, and RA diseases [4]. How-
ever, the involvement of the different prostanoid receptors
EP1-EP4 and their ligands such as prostaglandin E2
(PGE2) as well as their processing enzymes COX2 and
mPGES-1 has not been systematically investigated.
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Prostaglandin E2 (PGE2) is an arachidonic acid deriva-
tive generated by the actions of COX2 (prostaglandin-endo-
peroxide synthase-2) and microsomal PGES-1 (mPGES-1)
and acts as a potent proinflammatory lipid mediator. Emerg-
ing evidence suggests that PGE2 and COX-2 are produced
during the course of OA and other inflammatory diseases
[5]. Furthermore, the induction of both PGE2 and COX-2
was observed in the primary culture of rheumatoid synovial
cells after the in vitro treatment with proinflammatory
cytokines [5]. The PGE2 binds to a specific group of seven
transmembrane domain receptors belonging to the G-
protein-coupled “endogenous pyrogen” or EP receptor super
family. Activation of these receptors results in physiological
and pharmacological effects on cell growth and function [6]
as well as in the inflammatory process of arthritis [7]. PGE2
receptors include four subtypes, i.e., the EP1-4 receptors [8,
9]. Largo et al. [10] suggested that endogenous PGE2 might
control the propagation of inflammatory processes within
the inflamed synovium, whereas Inoue et al. [11] demon-
strated in isolated human fibroblasts from OA and RA
patients that PGE2 regulated the production of IL-6 and vas-
cular endothelial growth factor via activation of EP2 and EP4
receptors. Moreover, Li et al. [12] showed that stimulation of
human articular chondrocytes with PGE2, interleukin-1 (IL-
1), and tumor necrosis factor-alpha (TNF-α) upregulated the
expression of EP2 and EP4 in human chondrocytes in vitro.
The authors suggested that these receptor subtypes may ini-
tiate the endogenous PGE2-signaling cascade and may serve
as an important target for therapeutic regimens in order to
prevent the progression of arthritic disease.
Although, there is accumulating data suggesting that
PGE2 are implicated in arthritic diseases through the activa-
tion of their EP receptors (EP1, EP2, EP3, and EP4), there is
no comprehensive study which had thoroughly examined the
exact cell types and disease-specific differences in the occur-
rence of the components of the prostanoid system including
EP1-4 receptor subtypes and endogenous ligand PGE2 with
its processing enzymes mPGES-1 and COX-2 in various
types of synovial disease. We, therefore, systemically investi-
gated the distribution, localization and abundance of PGE-2,
its processing enzymes COX-2, and mPGES-1, as well as its
corresponding prostanoid receptor subtypes EP1-4 within
the synovium of patients with joint trauma (JT), osteoarthri-
tis (OA), and rheumatoid arthritis (RA). Moreover, we deter-
mined the number and types of cells expressing these
components of the prostanoid system by the use of various
cell markers for synovial fibroblasts (P4HB), macrophages/-
monocytes (CD68), granulocytes (CD15), T lymphocytes
(CD3), and plasma cells (Ab-1).
2. Materials and Methods
2.1. Patients and Synovial Sample Collection. Synovium biop-
sies of patients were obtained from three different clinics:
DRK Clinic Westend Berlin, Landeskrankenhaus Klagenfurt
(Austria), and the University Hospital Regensburg. This
study was approved by the ethical committees of the
Charité-Universitätsmedizin Berlin (Germany), the Univer-
sity Hospital of Regensburg (Germany), and the Landeskran-
kenhaus Klagenfurt (Austria). Patients’ approval was
obtained from all three locations, and patients gave their
written agreement to the contribution in this study after they
were informed about the purpose of this study (EA1/052/12).
According to the criteria of the American College of Rheu-
matology/and European league [13] and the clinical and
radiological criteria of OA [14], synovial tissues were col-
lected from patients diagnosed with joint trauma, osteoar-
thritis, and rheumatoid arthritis. In addition, synovium
samples collected from patients who were subjected to a diag-
nostic arthroscopy were used as a control. During the sur-
gery, synovial tissues were taken from patients and then
divided into two pieces, one piece was embedded directly into
4% paraformaldehyde for immunohistochemistry, and the
other piece was placed on dry ice for quantitative
TaqMan®-PCR for all four groups and then stored at -80°C.
2.2. Quantitative TaqMan®-PCR. Total RNA was extracted
from synovial tissue samples of 4 patients of each group
(n = 4) by using the commercially available kit QIAzol Lysis
Reagent (Qiagen, Hilden, Germany) as described previously
[4]. For cDNA synthesis, 500 ng total RNA was isolated by
NanoDrop (Peqlab). Then, 500ng total RNA was converted
to cDNA at 42°C for 1 h using the Omniscript RT Kit
(Qiagen, Hilden, Germany) as described previously [4]. The
obtained DNA was stored at −20°C. Specific primers for
COX-2, mPGEs-1, EP1, EP2, EP3, EP4, and 18s were used
(detailed information of primers in Table S1). Finally,
quantitative TaqMan®-PCR was performed using a SYBR®
Green kit according to the manufacturer’s protocol
(Applied Biosystems). Amplification was performed with 40
cycles, each consisting of 15 s at 95°C and of 30 s at 60°C.
To detect fluorescence specific products for each primer
pair, the reaction was carried out at a temperature just
below the specific melting temperature (Tm) as described
previously [4]. For statistical analysis, experiments were
performed in triplicate in order to determine COX-2, EP1,
EP2, EP3, EP4, and mPGES-1 mRNA by the delta-delta CT
method as described previously [4].
2.3. Tissue Preparation and Histological Evaluation. Biopsies
of synovial tissue were fixed in 4% (w/v) paraformaldehyde,
dissolved in 0.16M phosphate buffer solution (PBS)
(pH7.4) for 4 hours, and then cryoprotected overnight at
4°C in PBS containing 10% sucrose. Tissue sections (8μm)
were prepared using a Cryostat (Thermo Fisher, Driesch,
Germany) and then mounted onto gelatin-coated slides.
Intact synovial tissue was subjected to hematoxylin-eosin
histological evaluation identifying the components of lining
cell layers and sublining cells as previously described [15,
16]. Cell populations were counted in 3 different tissue
sections from 5 patients of each group of diseases by a
blinded experimenter (400x magnification) except for the
control group (n = 4). The lining-layer thickness was
assessed by those lining cells only with a visible nucleus
in a cross-section at different sites along the entire length
of the lining layers and calculated from at least three
sections (n = 5/group) and three fields per section (400x
magnification) [17].
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2.4. Single and Double Immunofluorescence Staining
Procedures. Immunofluorescence staining was performed as
described previously [18, 19]. Briefly, the mounted tissue
sections were incubated with PBS containing 0.3% Triton
X-100, 1% BSA, 10% goat serum, donkey serum, and horse
serum (Vector Laboratories, CA, USA) (blocking solution)
in order to block nonspecific staining. Then, sections were
incubated overnight at 4° C with the following primary anti-
bodies (Table S2): anti-Cox-2, anti-mPGEs-1, anti-PGE2,
anti-EP1, anti-EP2, anti-EP3, anti-EP4 alone or in
combination with anti-P4HB, anti-CD3, and anti-Ab-1,
anti-CD15, or anti-CD68. In addition, some sections were
incubated as follows: anti-COX-2/EP3 or anti-PGE2/anti-
EP3. Then, the tissue sections were washed in PBS and
incubated with Alexa Fluor 594 donkey anti-rabbit
antibody alone or in combination with Alexa Fluor 488
donkey anti-goat or with Alexa Fluor 594 donkey anti-
mouse (Invitrogen, Germany). Finally, the tissue sections
were washed in PBS, and then, the nuclei were stained with
DAPI (4′,6-diamidino-2-phenylindole) and mounted in
VECTASHIELD (Vector Laboratories). To demonstrate the
specificity of staining, the following controls were included:
omission of the primary antisera or the secondary
antibodies, as described in our previous studies. The images
were performed using a confocal laser scanning microscope,
LSM510, as described previously [4]. The number of COX-2,
PGE2, EP1, EP2, EP3, and EP4 immunoreactive cells was
counted by a blinded experimenter in three sections per
patient (control n = 4 patients, JT n = 5 patients, OA n = 5
patients, RA n = 5 patients).
2.5. Statistical Analysis. Data were calculated as means ±
SEM. Comparisons between different groups were performed
using one-way analysis of variance (ANOVA) followed by
Tukey’s test in the case of normally distributed data and the
Kruskal–Wallis analysis of variance on ranks followed by
Dunn’s test in the case of data not normally distributed.
The data were significantly different if P < 0:05. All statistical
tests were performed using the Sigma Plot 13.0 statistical
software.
3. Results
3.1. Patients’ Characteristics and Synovial Immune Cell
Profile. Of 42 patients screened, seven patients had to be
excluded from the present study after histological examina-
tion because the tissue samples lacked the basic structure of
human synovium. The remaining 35 patients were classified
dependent on their clinical diagnosis as follows: control (5
patients), JT (9 patients), OA (11 patients), and RA (10
patients). Patients’ demographics such as patient’s age,
gender, disease duration, and medications are presented in
Table 1. In addition, our light microscopic analysis of syno-
vial tissues showed that lining-layer thickness, overall cellu-
larity, and vascularity were significantly increased in RA,
OA, and JT patients compared to control (P < 0:05, one-
way ANOVA followed by Tukey’s test) (Table 1). Impor-
tantly, we further characterized the synovial cellularity in
greater detail by double immunofluorescence confocal
microscopy for various types of immunocytes and fibro-
blasts. Indeed, characterization of these cells revealed abun-
dant granulocytes and macrophages within synovium
following JT, numerous fibroblasts and macrophages within
osteoarthritic synovium, and most prominently plasma cells,
fibroblasts, and macrophages within rheumatoid synovium
(P < 0:05, Kruskal–Wallis ANOVA on ranks followed by
Dunn’s test) (Figure S1).
3.2. Distinct Expression of Prostaglandin E2 (PGE2) as well as
Processing Enzymes mPGES-1 and COX-2 in Human
Synovium in Various Forms of Inflammatory Joint Disease.
Quantitative analysis of double immunofluorescence staining
of synovial tissues showed that the number of PGE2-IR cells
was significantly higher within lining and sublining layers of
rheumatoid, osteoarthritic, and joint trauma synovium com-
pared to controls (P < 0:05; Kruskal–Wallis ANOVA on
ranks followed by Dunn’s test); however, it was most abun-
dant in RA patients (Figure 1). Quantitative TaqMan®-PCR
investigation showed that mPGES-1 (Figure 2(a)) and
COX-2 (Figure 3(a)) specific mRNA was significantly higher
in synovial tissue of JT, OA, and RA patients compared to
Table 1: The clinical and histological data characterizing the patients with joint trauma, osteoarthritis, and rheumatoid arthritis.
Patient Nr. Control (n = 5) JT (n = 9) OA (n = 11) RA (n = 10)
Age (years) 65 (±16,8) 48 (±17) 72 (±6) 64.9 (±17)
Sex (F/M) 1/4 6/4 7/3 4/6
Disease duration
≤1 year 5/5 7/10 3/10 —
>1 year — 3/10 7/10 10/10
Drugs: NSAIDs (Diclofenac, Ibuprofen, Profenid,
Paracetamol, and Dipyrone)
5/5 8/10 9/10 8/10
Etoricoxib NA 1/9 4/10 1/10
Prednisolon (dexamethasone) NA NA NA 8/10
Lining-layer thickness (cell layers) 1 (1 : 2) 2 (1: 3) 3∗ (3: 4) 4∗ (3: 5)
Overall cellularity (cells/mm2) 45 (44; 49) 119∗ (97; 138) 275∗# (220; 285) 390∗# (358; 474)
Vascularity (vessels) 2 (1; 3) 3 (3; 5) 6∗ (5; 7) 6∗ (3; 8)







































Figure 1: Detection of prostaglandin-E2 (PGE2) in patients with joint trauma (JT), osteoarthritis (OA), and rheumatoid arthritis (RA). (a)
Quantitative analysis of immunofluorescence microscopy for synovial PGE2-IR cells relative to the synovium of controls (data are shown as
means ± SEM; P < 0:05, Kruskal–Wallis ANOVA on ranks followed by Dunn’s test). (b) Immunofluorescence microscopy shows that the
number of PGE2-IR cells (Texas red fluorescence) is increased in various forms of inflammatory joint disease compared to controls which
































































Ctrl JT OA RA
(c)
Figure 2: Detection of microsomal prostaglandin E synthase-1 (mPGES-1) mRNA (a) and the number of mPGES-1-IR cells (b) in patients
with joint trauma (JT), osteoarthritis (OA) and rheumatoid arthritis (RA). (a, b) Quantification of mPGES-1 mRNA (a) and
immunofluorescence positive cells (b) shows that mPGES-1 expression was more prominent in various forms of inflammatory joint
disease compared to synovium of controls; however, in patients with RA and OA, it was significantly higher compared to JT (Data are
shown as means ± SEM, P < 0:05, one-way ANOVA followed by Tukey’s test). C: Immunofluorescence microscopy for mPGES (FITC
green fluorescence) shows that the number of synovial mPGES-IR cells is increased in various forms of inflammatory joint disease
compared to controls which was highest in osteoarthritic synovium. DAPI blue fluorescence shows nuclear staining. Bar = 20 μm.
(∗P < 0:05, compared to control; #P < 0:05, compared to JT patients).



































































Ctrl JT OA RA
(c)
Figure 3: Detection of cyclooxygenase 2 (COX2) mRNA (a) and the number of COX-IR cells (b, c) in patients with joint trauma (JT),
osteoarthritis (OA), and rheumatoid arthritis (RA). Quantification of COX-2 mRNA (a) and immunofluorescence positive cells (b) shows
that COX-2 expression was more prominent in JT, OR, and RA compared to synovium of controls (data are shown as means ± SEM, P <
0:05, one-way ANOVA followed by Tukey’s test). (c) Immunofluorescence microscopy for COX-2 (Texas red fluorescence) shows more
abundant COX-2-IR cells in JT, OR, and RA compared to control synovium. SEM. DAPI blue fluorescence shows nuclear staining. Bar =






























































Ctrl JT OA RA
(c)
Figure 4: Detection of PGE-2 receptor 1 (EP1 receptor) mRNA (a) and number of EP1-IR cells (b, c) in patients with joint trauma (JT),
osteoarthritis (OA), and rheumatoid arthritis (RA). (a) Quantification of EP1 mRNA shows that EP1 mRNA was more prominent in
various forms of inflammatory joint disease compared to control synovium (data are shown as means ± SEM, P < 0:05, one-way ANOVA
followed by Tukey’s test). (b) Quantitative analysis of immunofluorescence microscopy for EP1-IR cells relative to control synovium (data
are shown as means ± SEM, P < 0:05, Kruskal–Wallis ANOVA on ranks followed by Dunn’s test). (c) Immunofluorescence microscopy
shows more abundant EP1-IR cells (Texas red fluorescence) in JT, OA, and RA compared to control synovium. DAPI blue fluorescence
































































Ctrl JT OA RA
(c)
Figure 5: Detection of PGE-2 receptor 2 (EP2 receptor) mRNA (a) and number of EP2-IR cells (b, c) in patients with joint trauma (JT),
osteoarthritis (OA), and rheumatoid arthritis (RA). (a) Quantification of EP2 mRNA shows that EP2 mRNA was significantly higher in
JT, OA, and RA compared to control synovium (data are shown as means ± SEM, P < 0:05, one-way ANOVA followed by Tukey’s test).
(b) Quantitative analysis of immunofluorescence microscopy for EP2-IR cells relative to the control synovium (data are shown as means
± SEM, P < 0:05, Kruskal–Wallis ANOVA on ranks followed by Dunn’s test). (c) Immunofluorescence microscopy shows more abundant
EP2-IR cells (Texas red fluorescence) in rheumatoid and osteoarthritic synovium compared to JT and control. DAPI blue fluorescence


































































Ctrl JT OA RA
(c)
Figure 6: Detection of PGE-2 receptor 3 (EP3 receptor) mRNA (a) and number of EP3-IR cells (b, c) in patients with joint trauma (JT),
osteoarthritis (OA), and rheumatoid arthritis (RA). (a) Quantification of EP3 mRNA shows that EP3 mRNA was significantly higher in
JT, OA, and RA compared to control synovium (data are shown as means ± SEM, P < 0:05, one-way ANOVA followed by Tukey’s test)
but was more prominent in OA and RA. (b) Quantitative analysis of immunofluorescence microscopy for EP3-IR cells relative to the
control synovium (data are shown as means ± SEM, P < 0:05, Kruskal–Wallis ANOVA on ranks followed by Dunn’s test). (c)
Immunofluorescence microscopy shows more abundant EP3-IR cells (Texas red fluorescence) in RA and OA compared to JT and control
synovium. DAPI blue fluorescence shows nuclear staining. Bar = 20 μm. (∗P < 0:05, compared to control).
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controls (P < 0:05; one-way ANOVA followed by Tukey’s
test); however, it was most prominent in RA synovium. In
parallel, mPGES-1- and COX-2-IR cells detected in lining
and sublining layers of human synovium were significantly
elevated in their number in patients with JT, OA, and RA
compared to controls (P < 0:05), (Figures 2(b), 2(c), 3(b),
and 3(c)). Double immunofluorescence confocal microscopy
showed that PGE2 and mPGES-1 as well as COX2 coloca-
lized predominantly in granulocytes and P4HB-IR
fibroblasts of patients with JT (data not shown) and in
CD68-IR macrophages as well as P4HB-IR fibroblasts of
patients with OA and RA (data not shown). All three com-
ponents of the prostanoid system were separately identified
in large populations of Ab-1 plasma cells in RA patients only
(data not shown).
3.3. Distinct Expression of Prostanoid Receptor Subtypes EP1,
EP2, EP3, and EP4 in Human Synovium in Various Forms of
Inflammatory Joint Disease. Quantitative TaqMan®-PCR
analysis of specific mRNA for prostanoid receptor subtypes
EP1, EP2, and EP3 demonstrated a significant higher expres-
sion in the synovium of JT, OA, and RA patients compared to
controls (P < 0:05) (Figures 4(a), 5(a), and 6(a)), except for
the EP4 specific mRNA that was not significantly elevated
in JT patients (Figure 7(a)). In parallel, the immunofluores-
cence confocal microscopy of synovial tissues revealed
similar increases in the number of EP1-, EP2-, EP3-, and
EP4-IR cells compared to control synovium (Figures 4(b),
4(c), 5(b), 5(c), 6(b), 6(c), 7(b), and 7(c)). Double immuno-
fluorescence confocal microscopy showed that prostanoid
receptor subtypes EP2 and EP3 were mainly expressed in
CD15-IR granulocytes of JT synovium (e.g., Figure S2) and
predominantly identified in CD68-IR macrophages and
P4HB-IR fibroblasts of OA (e.g., Figure S3) and RA
synovium, whereas they were seen to a large extent in Ab-1
plasma cells only in RA synovium (e.g., Figure S4).
3.4. Distinct Expression Profiles of the Prostanoid System in
Synovium of JT, OA, and RA Patients. To visualize the
expression profiles of the different components of the
prostanoid system within a single-patient group (JT, OA,
or RA patients), the data for COX-2, EP1-EP4, mPGEs-1,
and PGE-2 were converted to and displayed as fold change
over control for that individual group (Figures 8–10).
Inferring from this, the data show in the synovium of JT
patients that the COX-2-expressing cells are the most
abundant, followed by EP1-3- and PGE-2-expressing cells
(Figure 8). In contrast, in the synovium of OA patients,
it emerges that the EP3-expressing cells are the most abun-
dant followed by the PGE-2- and COX-2-expressing cells
(Figure 9). Finally, the synovium of the RA patients reveals
that the PGE-2-expressing cells are the most abundant,
followed by the EP3- and COX-2-expressing cells and,


































































Ctrl JT OA RA
(c)
Figure 7: Detection of PGE-2 receptor 4 (EP4 receptor) mRNA (a) and number of EP3-IR cells (b, c) in patients with joint trauma (JT),
osteoarthritis (OA), and rheumatoid arthritis (RA). (a) Quantification of EP4 mRNA shows that EP4 mRNA was significantly higher in
rheumatoid and osteoarthritic synovium compared to JT and control (data are shown as means ± SEM, P < 0:05, one-way ANOVA
followed by Tukey’s test). (b) Quantitative analysis of immunofluorescence microscopy for EP3-IR cells relative to the control synovium
(data are shown as means ± SEM, P < 0:05, Kruskal–Wallis ANOVA on ranks followed by Dunn’s test). (c) Immunofluorescence
microscopy shows more abundant EP3-IR cells (Texas red fluorescence) in JT, OR, and RA compared to control synovium. DAPI blue
fluorescence shows nuclear staining. Bar = 20 μm. (∗P < 0:05, compared to control, #P < 0:05, compared to JT).
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4. Discussion
Different joint diseases such as joint trauma, osteoarthritis,
and rheumatoid arthritis show a distinct inflammatory
response within synovial tissue [13, 20]. This study systemat-
ically investigated potential differences in the abundance of
PGE-2, its processing enzymes COX-2 and mPGES-1, and
its corresponding prostanoid receptor subtypes EP1-4 within
the synovial tissue of JT, OA, and RA patients in direct com-
parison to each other and to controls who simply underwent
a diagnostic arthroscopy. In line with our mRNA data,
immunoreactive cells for PGE2- (13-fold) and its processing
enzymes COX-2- (9-fold) and mPGES-1- (2.4-fold) were
highest in the synovial tissue of RA patients compared to
controls, followed by synovial tissue of OA patients (9-fold,
7-fold, and 2.6-fold, respectively) and of JT patients (5.8-fold,
7.5-fold, and 2-fold, respectively). Identification of the corre-
sponding prostanoid receptor subtypes within the synovial
tissue of these patients revealed that the EP3 prostanoid
receptor subtype was the most abundant in all three groups
of patients (RA patients: 10-fold; OA patients: 11-fold; and
JT patients: 5-fold) followed by the other prostanoid receptor
subtypes (EP1-EP3) which differed not much among each
other (RA: ca. 5-fold; OA: ca. 4-fold; and JT: ca. 3-fold). Fur-
ther identification of the most abundant immune cells within
synovial tissue expressing the different components of the
prostanoid system showed predominantly granulocytes
(CD15) and fibroblast-like synoviocytes (P4HB) in JT
patients, mainly macrophages (CD68) and fibroblast-like
cells (P4HB) in OA patients, and mostly plasma (AB-1),
macrophages (CD68), and fibroblast-like-synoviocytes
(P4HB) in RA patients. Taken together, direct comparison
of the different components of the prostanoid system within
the synovial tissue of JT, OA, and RA patients in a single
experimental approach showed the highest abundance in
RA followed by OA and JT patients, a predominant expres-
sion of the EP3 receptor in all three groups and a distinct
profile of immune cells involved.
For a long time, it has been known that prostaglandins
such as PGE-2—assessed by a radioimmunoassay—are
elevated in the synovial fluid of patients suffering from RA,
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JT EP3 COX-2 EP3/COX-2 DAPI
(c)
Figure 8: Detection of mRNA (a) and the number of cells immunoreactive for different components of the prostanoid system (PGE2,
mPGES, COX-2, and EP1-4) (b) in patients with joint trauma (JT). (a) Quantification of mRNA specific for COX2, EP1-4, and mPGEs-1
in synovium of JT patients. (b) Quantitative comparison of COX2-, EP1-4-, and mPGEs-1-IR cells in synovium of JT patients. Data are
shown as means ± SEM. (c) Confocal microscopy of EP3 (Texas red fluorescence; a, b) and mPGES or COX2 (FITC green fluorescence;
c, d) double immunofluorescence (e–h) in JT synovium. DAPI blue fluorescence shows nuclear staining. Bar = 40μm.
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from the synovial fluid of RA patients, as well fibroblast-like
synoviocytes, isolated from the synovium of RA [23–26] and
OA patients [27], release PGE-2. Further experiments dem-
onstrated that inhibition of the COX enzyme prevented the
production and release of PGE-2 in rheumatoid synovial
fibroblasts [28], and the PGE-2 processing enzymes were
identified by RT-PCR or Western blot as COX-1, COX-2,
and PGES-1 within the synovium of RA [23, 25, 28, 29]
and of OA patients [12, 30, 31]. Only recently, COX-1,
COX-2, and PGES-1 were demonstrated by immunohisto-
chemistry within the synovium of RA patients [32, 33]. Our
findings go beyond these studies in that we systematically
compared among JT, OA, and RA patients the synovial
expression (mRNA) and abundance (immune fluorescence
microscopy) of PGE-2 with its processing enzymes COX-1,
COX-2, and PGES-1 within a single experimental approach.
These components of the prostanoid system were identified
in all three groups of patients; however, they were highest
in RA patients, followed by OA and JT patients.
In light of these findings, we further assessed which pros-
tanoid receptor subtypes were expressed most prominently
within the synovium of JT, OA, and RA patients. Intrigu-
ingly, the EP3 prostanoid receptor subtype was the most
abundant in all three groups of patients (5- to 11-fold over
control), followed by a similar, but lower expression of the
EP1, EP2, and EP4 receptors. Consistent with previous stud-
ies in mainly rheumatoid synovial fibroblasts [34, 35], we
found an enhanced expression (3- to 5-fold) of the EP1,
EP2, and EP4 receptors within the synovium of JT, OA,
and RA patients. Experimental studies with knockout mice
indicated that the EP4 receptor knockout was able to signifi-
cantly decrease the incidence and severity of arthritis,
whereas the EP1-EP3 receptors essentially do not contribute
to the inflammatory process of arthritis [36, 37]. What stands
out from our results is that the EP3 receptor was highly
prominent in its abundance within the synovial tissue of all
three groups of patients. Previous experimental studies with
EP3 receptor knockout mice demonstrated a significant anti-
nociceptive effect in which the putative mechanism is still
unclear [2, 38]. More recently, EP3 receptors have been
shown in fibroblasts and peripheral nerve bundles of synovial









































































































Figure 9: Detection of mRNA (a) and the number of cells immunoreactive for different components of the prostanoid system (PGE2,
mPGES, COX-2, and EP1-4) (b) in patients with osteoarthritis (OA). (a) Quantification of mRNA specific for COX2, EP1-4, and mPGEs-
1 in synovium of OA patients. (b) Quantitative analysis of COX2-, EP1-4-, and mPGEs-1-IR cells in OA synovium. Data are shown as
means ± SEM. (c) Confocal microscopy of EP3 (red fluorescence; a, b) and mPGES or COX2 (green fluorescence; c, d) double
immunofluorescence (e–h) in OA synovium. Bar = 40μm. DAPI blue fluorescence shows nuclear staining. Bar = 40 μm.
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antinociceptive effects in an experimental study, in contrast
to the described proinflammatory effects of EP2 and EP4
receptors [39]. Also, Attu et al. [40] stated that prostaglandin
E2 exerts catabolic effects in osteoarthritis cartilage via the
EP4 receptor. Previous studies reported that the PGE2 signal
through the EP2 receptor promotes the growth of articular
chondrocytes [41] or enhances the regeneration of injured
articular cartilage [42].
Our immunofluorescence confocal microscopy analysis
revealed that prostanoid receptor subtypes (EP1-4) were
expressed predominantly in synovial granulocytes (CD15)
of JT patients, in fibroblast-like synoviocytes (P4HB) and
macrophages (CD68) of OA patients and in macrophages
as well as plasma cells of RA patients. This is consistent with
a previous study by Dechanet et al. [43] which stated that
plasma cells were identified as clusters in close contact with
macrophages, synoviocytes, and CD8+ T-cells within rheu-
matoid synovium [43]. Using double immunofluorescence
confocal microscopy, we identified EP1 and EP4 also in high
populations of mature B-lymphocytes such as plasma cells
within synovium of RA patients extending previous studies
by Fedyk et al. [44] which demonstrated mRNA encoding
EP1, EP3, and EP4 receptors in normal and transformed B-
lymphocytes. Collectively, the present findings suggest that
prostanoid receptor subtypes and PGE2 with its processing
enzymes mPGES-1 and COX-2 expressed in distinct cell
populations may differentially mediate the inflammatory
process within JT, OA, and RA synovium.
Our study certainly has its limitations in that the num-
ber of patients’ samples is low and does not necessarily
allow generalization of our results to a larger population
of patients. Moreover, the inflammatory process during JT,
OA, and RA arthritis is a dynamic process, and our synovial
tissue samples obtained give only a cross-sectional picture
of these patients at a specific moment of their disease. In
addition, differences in the patients’ daily medications
might have influenced the results. Thus, one can only cau-
tiously draw conclusions from our results. An advantage
of our study though is that we compared the different
synovial tissues within a single experimental approach so









































































































Figure 10: Detection of mRNA (a) and the number cells immunoreactive for different components of the prostanoid system (PGE2, mPGES,
COX-2, and EP1-4) (b) in patients with rheumatoid arthritis (RA). (a) Quantification of mRNA specific for COX2, EP1-4, and mPGEs-1 in
RA synovium. (b) Quantitative analysis of COX2-, EP1-4-, and mPGEs-1-IR cells in rheumatoid synovium. Data are shown asmeans ± SEM.
(c) Confocal microscopy of EP3 (red fluorescence; a, b) and mPGES or COX2 (green fluorescence; c, d) double immunofluorescence (e–h) in
RA synovium. DAPI blue fluorescence shows nuclear staining. Bar = 40μm.
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Taken together, our direct comparison of the different
components of the prostanoid system within the synovial tis-
sue of JT, OA, and RA patients in a single experimental
approach showed the highest abundance in RA followed by
OA and JT patients, a predominant expression of the EP3
receptor in all three groups and a distinct profile of immune
cells involved.
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Supplementary Materials
Table S1: characterization of the primers used for PCR. Table
S2: characterization of primary antibodies used. Figure S1:
quantitative analysis of immunofluorescence microscopy of
various types of immune cells and fibroblasts showing the
number of overall synovial cellularity. Note that the number
of immune cells and fibroblasts within OA and RA synovium
was significantly higher compared to JT patients and controls
(P < 0:05, Kruskal–Wallis ANOVA on ranks followed by
Dunn’s test). Moreover, granulocytes and macrophages were
most prominent in JT, but fibroblasts and macrophages were
more abundant in OA. In RA patients, the plasma cells, fibro-
blasts, and macrophages were the most abundant compared
to controls (P < 0:05, Kruskal–Wallis ANOVA on ranks
followed by Dunn’s test). Data are shown as means ± SEM.
(∗P < 0:05, compared to control, #P < 0:05, compared to JT,
and P < 0:05, compared to OA), (in Granulocyte; §P < 0:05,
compared to OA and RA). Figure S2: double immunofluores-
cence confocal microscopy of prostaglandin E2 receptor 3
(EP3) (red fluorescence; a, e, and i) with CD68 (b), P4HB
(f), or CD15 (j) (green fluorescence) in synovial tissue of
patients with joint trauma (JT). Note that the majority of
EP3 immunoreactive cells coexpress CD15 (granulocyte)
and P4HB (fibroblast) but not CD68 (macrophage) in JT
synovium. Bar = 20 μm. Figure S3: double immunofluores-
cence confocal microscopy of PGE-2 receptor 3 (EP3) (red
fluorescence; a, e, and i) with CD68 (b) or P4HB (f) (green
fluorescence) in synovial tissue from patients with osteoar-
thritis (OA). Note that a high population of EP3 immunore-
active cells coexpress P4HB or CD68 in OA synovium.
Bar = 20 μm. Figure S4: double immunofluorescence confo-
cal microscopy of PGE-2 receptor 3 (EP3) (red fluorescence;
a, e, and i) with CD68 (b), P4HB, or Ab-1 (plasma cells) (f)
(green fluorescence) in synovial tissue from patients with
rheumatoid arthritis (RA). Note that a high population of
EP3 immunoreactive cells coexpress CD68 (macrophage),
P4HB (fibroblast), or Ab-1 (plasma cells) in OA synovium
(a–d). Bar = 20μm. (Supplementary Materials)
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